# US 2009/0275044 A1 · METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS mRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275044 A1
- Document ID: US20090275044A1
- Status: Published application
- Kind: A1
- Application number: 12/483,860
- Filed: 2009-06-12
- Published: 2009-11-05
- Earliest claimed: 2002-01-07
- Assignees: Norchip A/S
- Inventors: Frank Karlsen
- Web page: https://patentgrep.com/patent/US20090275044A1

## CPC

- C12Q 1/708: {for papilloma}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/16: Primer sets for multiplex assays
- Y10S 435/975: Kit
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

## Claims

### Claim 1

An in vitro method of screening a human subject for the presence of integrated HPV or a modified episomal HPV genome, which method comprises screening the human subject for expression of full length mRNA transcripts from the E6 gene of human papillomavirus, wherein a subject positive for expression of full length E6 mRNA from at least one HPV type are scored as carrying integrated HPV or a modified episomal HPV genome.

### Claim 2 (depends on 1)

The method of claim 1 wherein the human subject is previously identified as infected with human papillomavirus DNA in cells of the cervix.

### Claim 3 (depends on 1)

The method of claim 1 wherein the human subject has a previous diagnosis of ASCUS, CIN 1 lesions or condyloma.

### Claim 4 (depends on 1)

The method of claim 1 which comprises screening for expression of full length E6 mRNA transcripts from at least HPV type 16, wherein a subject positive for expression of full length E6 mRNA from at least HPV type 16 is scored as carrying integrated HPV or a modified episomal HPV genome.

### Claim 5 (depends on 4)

The method of claim 4 wherein said full length E6 mRNA transcripts of HPV type 16 contain all of the region from nucleotide 97 to nucleotide 880 in the E6 open reading frame, inclusive of nucleotides 97 and 880.

### Claim 6 (depends on 1)

The method of claim 1 wherein screening for E6 mRNA expression is carried out using an amplification reaction to amplify a region of the mRNA, together with real-time detection of the products of the amplification reaction.

### Claim 7 (depends on 6)

The method of claim 6 wherein screening for E6 mRNA expression is carried out using real-time NASBA.

### Claim 8

An in vitro method of identifying human subjects having abnormal cell changes in the cervix, which method comprises screening a human subject for expression of full length mRNA transcripts of the E6 gene of HPV, wherein a human subject positive for expression of full length E6 mRNA from at least one HPV type is identified as having abnormal cell changes in the cervix.

### Claim 9 (depends on 8)

The method of claim 8 wherein the human subject is previously identified as infected with human papillomavirus DNA in cells of the cervix.

### Claim 10 (depends on 8)

The method of claim 8 wherein the human subject has a previous diagnosis of ASCUS, CIN 1 lesions or condyloma.

### Claim 11 (depends on 8)

The method of claim 8 which comprises screening for expression of full length E6 mRNA transcripts from at least HPV type 16, wherein a subject positive for expression of full length E6 mRNA from at least HPV type 16 is scored as carrying integrated HPV or a modified episomal HPV genome.

### Claim 12 (depends on 11)

The method of claim 11 wherein said full length E6 mRNA transcripts of HPV type 16 contain all of the region from nucleotide 97 to nucleotide 880 in the E6 open reading frame, inclusive of nucleotides 97 and 880.

### Claim 13 (depends on 8)

The method of claim 8 wherein screening for E6 mRNA expression is carried out using an amplification reaction to amplify a region of the mRNA, together with real-time detection of the products of the amplification reaction.

### Claim 14 (depends on 13)

The method of claim 13 wherein screening for E6 mRNA expression is carried out using real-time NASBA.
